Literature DB >> 2966788

Sensitivity of activated human lymphocytes to cyclosporine and its metabolites.

A Zeevi1, R Venkataramanan, G Burckart, C P Wang, N Murase, D H Van Thiel, T E Starzl, L Makowka, R J Duquesnoy.   

Abstract

Alloreactive T cells generated as clones from mixed lymphocyte cultures, or propagated from heart or liver transplant biopsies, were tested for secondary proliferation measured in the primed lymphocyte test in the presence of Cyclosporine A and metabolites fractionated from human bile. Significant differences were observed in Cyclosporine A sensitivity between various cell cultures ranging as high as 100-fold. The liver is the primary site of Cyclosporine A metabolism, which yields a number of hydroxylated and N-dimethylated derivatives that are eventually secreted into the bile. Bile was collected from adult liver transplant patients on Cyclosporine A therapy and following extraction with diethyl ether, separated by high pressure liquid chromatography. Thirteen fractions were tested for their effect on lymphocyte proliferation in concanavalin A activation, mixed lymphocyte cultures and primed lymphocyte test assays. The strongest immunosuppressive effect was found with fraction 8, which contained metabolite M17, which has a single hydroxylation in position 1. Only three other fractions 9, 10, and 13, which contained metabolites M1, M18, and M21, respectively, exhibited immunosuppressive activity, albeit much lower than that of Cyclosporine A. Differences in Cyclosporine A sensitivity among alloreactive T cells followed similar patterns with Cyclosporine A metabolites. Thus, the assessment of the Cyclosporine A effect must consider differences in drug sensitivity of lymphocytes involved in transplant immunity and the generation of metabolites with immunosuppressive activity.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2966788     DOI: 10.1016/0198-8859(88)90089-4

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  10 in total

Review 1.  In vitro assessment of FK 506 immunosuppressive activity in transplant patients.

Authors:  A Zeevi; R Venkataramanan; V Warty; G Eiras; M Woan; K Abu-Elmagd; M Alessiani; A Jain; A J Demetris; T Zerbe
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

Review 2.  Clinically significant drug interactions with cyclosporin. An update.

Authors:  C Campana; M B Regazzi; I Buggia; M Molinaro
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

3.  Serial evaluation of immune profiles of simultaneous bone marrow and whole organ transplant recipients.

Authors:  A Zeevi; M Pavlick; S Lombardozzi; R Banas; A S Rao; P Fontes; A J Demetris; R Shapiro; M Jordan; F Dodson
Journal:  Transplant Proc       Date:  1995-02       Impact factor: 1.066

4.  Cyclosporine and its metabolites in mother and baby.

Authors:  R Venkataramanan; B Koneru; C C Wang; G J Burckart; S N Caritis; T E Starzl
Journal:  Transplantation       Date:  1988-09       Impact factor: 4.939

5.  Cyclosporine measurement by FPIA, PC-RIA, and HPLC following liver transplantation.

Authors:  G J Burckart; A Jain; W Diven; R Venkataramanan; T E Starzl
Journal:  Transplant Proc       Date:  1990-06       Impact factor: 1.066

6.  Abbott's fluorescence polarization immunoassay for cyclosporine and metabolites compared with the Sandoz "Sandimmune" RIA.

Authors:  A Sanghvi; W Diven; H Seltman; T Starzl
Journal:  Clin Chem       Date:  1988-09       Impact factor: 8.327

7.  New approaches in the use of cyclosporine: with particular reference to the liver.

Authors:  T E Starzl
Journal:  Transplant Proc       Date:  1988-06       Impact factor: 1.066

8.  Isolation of 10 cyclosporine metabolites from human bile.

Authors:  C P Wang; N R Hartman; R Venkataramanan; I Jardine; F T Lin; J E Knapp; T E Starzl; G J Burckart
Journal:  Drug Metab Dispos       Date:  1989 May-Jun       Impact factor: 3.922

9.  Cyclosporine pharmacokinetics in liver transplant recipients: evaluation of results using both polyclonal radioimmunoassay and liquid chromatographic analysis.

Authors:  J M Tredger; J Grevel; N Naoumov; C M Steward; A A Niven; B Whiting; R Williams
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

10.  The kinetics of cyclosporine and its metabolites in bone marrow transplant patients.

Authors:  T L Schwinghammer; D Przepiorka; R Venkataramanan; C P Wang; G J Burckart; C S Rosenfeld; R K Shadduck
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.